United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$331.59 USD
-5.15 (-1.53%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $331.56 -0.03 (-0.01%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth C Momentum A VGM
Company Summary
Silver Spring, MD-based United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by Eli Lilly as Cialis for erectile dysfunction) tablets. Remodulin is approved for both subcutaneous (SC) and intravenous (IV) use.
The company is also focused on research and development efforts to address the shortage of transplantable organs and tissues through regenerative medicine and organ manufacturing.
The company licensed ...
Company Summary
Silver Spring, MD-based United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by Eli Lilly as Cialis for erectile dysfunction) tablets. Remodulin is approved for both subcutaneous (SC) and intravenous (IV) use.
The company is also focused on research and development efforts to address the shortage of transplantable organs and tissues through regenerative medicine and organ manufacturing.
The company licensed certain exclusive rights to commercialize Adcirca for the treatment of PAH in the United States from Lilly in November 2008. Adcirca/Cialis lost exclusivity in 2018 and generic versions are available.
In 2015, the company gained approval for Unituxin for the treatment of pediatric patients with high-risk neuroblastoma. The antibody has been developed under an agreement with the National Cancer Institute (NCI) of the United States National Institutes of Health (NIH).
In January 2019, United Therapeutics acquired the worldwide rights to manufacture and develop/commercialize Arena Pharmaceuticals’ (now a part of Pfizer) oral, potent, once-daily IP receptor agonist, ralinepag. Ralinepag is being developed in late-stage studies for PAH.
United Therapeutics also has a robust pipeline that includes new indications, formulations, and delivery devices for its existing products, as well as new products to treat PAH, pulmonary fibrosis and other conditions.
The company reported total revenues of $2.33 billion in 2023, up 20% year over year.
General Information
United Therapeutics Corporation
1000 SPRING ST
SILVER SPRING, MD 20910
Phone: 301-608-9292
Fax: 301-608-9291
Email: ir@unither.com
Industry | Medical - Drugs |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 8/7/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 6.24 |
Current Year EPS Consensus Estimate | 24.87 |
Estimated Long-Term EPS Growth Rate | 9.20 |
Exp Earnings Date | 8/7/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 336.74 |
52 Week High | 339.56 |
52 Week Low | 208.62 |
Beta | 0.55 |
20 Day Moving Average | 450,796.91 |
Target Price Consensus | 318.09 |
4 Week | 5.55 |
12 Week | 43.70 |
YTD | 53.14 |
4 Week | 3.91 |
12 Week | 30.25 |
YTD | 31.48 |
Shares Outstanding (millions) | 44.36 |
Market Capitalization (millions) | 14,936.34 |
Short Ratio | NA |
Last Split Date | 9/23/2009 |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | 0.00 |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 13.54 |
Trailing 12 Months | 15.92 |
PEG Ratio | 1.47 |
vs. Previous Year | 26.95% |
vs. Previous Quarter | 41.51% |
vs. Previous Year | 33.70% |
vs. Previous Quarter | 10.25% |
Price/Book | 2.80 |
Price/Cash Flow | 15.24 |
Price / Sales | 5.98 |
6/30/24 | NA |
3/31/24 | 18.72 |
12/31/23 | 17.72 |
6/30/24 | NA |
3/31/24 | 15.35 |
12/31/23 | 14.47 |
6/30/24 | NA |
3/31/24 | 3.77 |
12/31/23 | 4.41 |
6/30/24 | NA |
3/31/24 | 3.64 |
12/31/23 | 4.28 |
6/30/24 | NA |
3/31/24 | 42.05 |
12/31/23 | 42.31 |
6/30/24 | NA |
3/31/24 | 42.05 |
12/31/23 | 42.31 |
6/30/24 | NA |
3/31/24 | 55.28 |
12/31/23 | 54.75 |
6/30/24 | NA |
3/31/24 | 120.32 |
12/31/23 | 127.35 |
6/30/24 | NA |
3/31/24 | 2.53 |
12/31/23 | 2.44 |
6/30/24 | NA |
3/31/24 | 0.04 |
12/31/23 | 0.05 |
6/30/24 | NA |
3/31/24 | 3.61 |
12/31/23 | 4.77 |